Notably, S100B gene variants associated with higher expression have been linked to earlier PD onset, and pharmacological inhibition of S100B–RAGE signaling (e.g., via pentamidine) has shown neuroprotective effects in experimental models, suggesting that this pathway contributes causally to disease progression [197]. This evidence concerns the gene S100B and Parkinson disease.